Business Standard

Zydus Cadila gets tentative USFDA approval to market anti-cancer drug

Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules

Zydus

Zydus

Press Trust of India New Delhi
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules.
Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Palbociclib Capsules in the strengths of 75 mg, 100 mg, and 125 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.
Palbociclib is an anti-cancer medicine that interferes with the growth and spread of cancer cells in the body.
The company said the newly approved medication will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 302 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04.
Shares of Cadila Healthcare were trading 1.07 per cent lower at Rs 379.80 on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 24 2020 | 10:59 AM IST

Explore News